Medisafe, a leading digital therapeutics company specializing in digital companions, has been selected by UCB to develop branded digital drug companions for its antiepileptic medications, with greater capabilities to expand across additional brands. The digital companions streamline support for patients to access financial assistance, patient diaries, and doctor discussion guides throughout their treatment journey. UCB is launching both digital companions in November in support of National Epilepsy Awareness Month and the more than 3.4 million patients in the US who live with the neurological condition. 1 in 26 people in the US will develop epilepsy at some point in their
The post UCB taps Medisafe in development of digital companion to support patient engagement appeared first on Pharma Mirror Magazine.
